Phase I, Open Label, Single Center Safety Study of [F-18]FLT
A Phase I, Open Label, Single Center Safety Study of [F-18]FLT
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject may be male or female and of any race / ethnicity;
- At the time of study drug dosing, the subject has reached his or her 18th birthday;
- Subject has histologic diagnosis of one of the following malignancies - glioblastoma gliosarcoma, anaplastic mixed/anaplastic oligodendroglioma or (anaplastic) astrocytoma with lesion visible on CT or MR and minimum histological grade of III/IV;
- Subject with suspect radiation necrosis that are planned for re-section;
- Subject or subject's legally acceptable representative provides informed consent;
- Subject is capable of complying with study procedures and able to lie still in the PET scanner;
- Subject is capable of communicating with study personnel;
- Subject has adequate liver and kidney function
Exclusion Criteria:
- Subject is pregnant or nursing;
- Subject is anemic (as defined as a hemoglobin level <10);
- Subject has not received chemotherapy or radiation therapy within the two weeks prior to imaging.
- Subject has as reflected by a serum liver enzymes outside the normal laboratory reference range;
- Subject has a history of chronic liver disease, which may compromise liver function;
- Subject has kidney disease as reflected by a serum creatinine outside the normal laboratory reference range;
- Subject has prior history of stroke or other condition of the head or neck that, in the investigator's opinion, might affect circulation to the brain or image interpretation (examples include, but are not limited to, previous stroke with cystic softening and cerebral deformity, or arteriovenous malformation);
- Subject has a history of significant cerebrovascular disease;
- Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
- Subject has previously received [F-18]FLT at any time, or any other investigational product within the past two weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: I
|
One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging.
Each imaging dose contains no more than 6.1 micrograms of FLT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety will be demonstrated through analysis of adverse events in subjects enrolled in the trial who received study drug
Time Frame: 24 hr
|
24 hr
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Charles M Intenzo, MD, Thomas Jefferson University Hospital, 132 S 10th St Phila, PA 19107
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D0008186
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.